Royce & Associates LP decreased its holdings in Haemonetics Co. (NYSE:HAE) by 3.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,300 shares of the medical instruments supplier’s stock after selling 700 shares during the period. Royce & Associates LP’s holdings in Haemonetics were worth $1,731,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HAE. Wagner Bowman Management Corp purchased a new position in shares of Haemonetics in the second quarter worth about $224,000. Arjuna Capital purchased a new position in shares of Haemonetics in the second quarter worth about $224,000. Alpine Woods Capital Investors LLC purchased a new position in shares of Haemonetics in the first quarter worth about $236,000. Zeke Capital Advisors LLC purchased a new position in shares of Haemonetics in the second quarter worth about $244,000. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Haemonetics in the second quarter worth about $249,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

HAE has been the subject of several recent research reports. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a research note on Tuesday, June 12th. Barrington Research lifted their target price on shares of Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a research note on Thursday, August 9th. Morgan Stanley lifted their target price on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Finally, Jefferies Financial Group lifted their target price on shares of Haemonetics from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, June 14th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Haemonetics currently has a consensus rating of “Buy” and a consensus target price of $98.33.

In related news, CFO William P. Mr. Burke sold 841 shares of the business’s stock in a transaction that occurred on Thursday, October 25th. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Simon sold 3,595 shares of the business’s stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $40.39, for a total transaction of $145,202.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,880 shares of company stock valued at $1,284,307. 1.04% of the stock is owned by corporate insiders.

Shares of NYSE:HAE opened at $111.14 on Friday. The company has a market cap of $5.74 billion, a P/E ratio of 52.41, a PEG ratio of 4.57 and a beta of 1.01. Haemonetics Co. has a 12 month low of $41.54 and a 12 month high of $112.82. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.84 and a quick ratio of 1.94.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $0.59 EPS for the quarter, beating the consensus estimate of $0.42 by $0.17. The company had revenue of $229.35 million during the quarter, compared to analysts’ expectations of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. equities research analysts anticipate that Haemonetics Co. will post 2.28 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.